{"text": ["Novartis'", "Neuroendocrine", "Tumors", "Targeted", "Radiotherapy", "Takes", "Small", "Hit", "on", "Clinically", "Relevant", "Overall", "Survival"], "created_at": "2021-06-04 19:10:32"}
{"text": ["Novartis", "(NVS)", "Announces", "Data", "on", "Radioligand", "Therapy", "at", "ASCO"], "created_at": "2021-06-04 17:08:05"}
{"text": ["Novartis", "announces", "Tabrecta\u00ae", "first", "published", "overall", "survival", "and", "updated", "overall", "response", "data", "in", "patients", "with", "METex14", "metastatic", "NSCLC"], "created_at": "2021-06-04 13:05:00"}
{"text": ["Novartis", "investigational", "checkpoint", "inhibitor", "tislelizumab", "met", "primary", "endpoint", "of", "overall", "survival", "in", "pivotal", "Phase", "III", "trial", "of", "esophageal", "cancer", "after", "systemic", "therapy"], "created_at": "2021-06-04 13:00:00"}
{"text": ["Mesoblast", "(MESO)", "Q3", "2021", "Earnings", "Call", "Transcript"], "created_at": "2021-06-04 01:00:33"}
